Adenosine in the treatment of stroke: yes, maybe, or absolutely not?
Agonist stimulation of adenosine A(1) receptors has been consistently shown to result in reduction of brain damage following experimentally induced global and focal brain ischaemia in animals. Unsurprisingly, the use of adenosine A(1) receptors as targets for the development of clinical therapeutics suitable for treatment of ischaemic brain disorders has been suggested by many authors. The latest studies of adenosine and its receptors indicate that adenosine-mediated actions might be far more complex than originally anticipated, casting some doubt about the rapid development of stroke treatment based on adenosine. This review discusses the possible role of adenosine receptor subtypes (A(1), A(2) and A(3)) in the context of their potential as therapeutics in stroke.
von Lubitz
D K
DK
Emergency Medicine Research Laboratories, Department of Emergency Medicine, University of Michigan Medical Center, TC/B1354/0303, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0303, USA. dvlubitz@umich.edu
D000241:Adenosine / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy; D006801:Humans; D010716:Phosphatidylinositols / Q000378:metabolism; D018047:Receptors, Purinergic P1 / Q000145:classification / Q000502:physiology; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D010716:Phosphatidylinositols; D018047:Receptors, Purinergic P1; D000241:Adenosine